$CLSN Celsion Corporation to Hold First Quarter 2013

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz

$CLSN

Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013

LAWRENCEVILLE, N.J., May 1, 2013 /PRNewswire via COMTEX/ -- Celsion Corporation CLSN +7.66% , a leading oncology drug development company, today announced that it would hold a conference call to discuss first quarter 2013 results at 11:00 a.m. EDT on Thursday, May 9, 2013. To participate in the call, interested parties may dial 1-888-329-8862 (Toll-Free/North America) or 1-719-325-2376 (International/Toll) and ask for The Celsion Corporation First Quarter 2013 Financial Results Conference Call to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com .

The call will be archived for replay on Thursday, May 9, 2013 at 2:00 p.m. EDT and will remain available until Thursday, May 23, 2013. The replay can be accessed at 1-877-870-5176 (Toll-Free/North America) or 1-858-384-5517 (International/Toll) using Conference ID: 2227568. An audio replay of the call will also be available on the Company's website, http://www.celsion.com , for 30 days after 2:00 p.m. EDT on Thursday, May 9, 2013.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com .

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church Sr. Vice President - Corporate Strategy & Investor Relations 609-482-2455 jchurch@celsion.com

SOURCE Celsion Corporation

http://rt.prnewswire.com/rt.gif?NewsItemId=NY...d=20130501

Copyright (C) 2013 PR Newswire. All rights reserved

Comtex
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Siili Solutions Presents Financial Overview and Strategic Outlook

Updated Category News Views 169

Siili Solutions Highlights Key Financial Developments Siili Solutions Plc recently issued its financial statements, shedding light on its performance over the past year. As a dynamic player in the technology and digital services field, the company is strategically focusing on its growth prospects. However, the road has not been without hurdles, as noted in their latest...

Continue Reading
BTQ Technologies Boosts Quantum Security with Key Acquisition

Updated Category News Views 225

BTQ Technologies Enhances Quantum Security Through Strategic Acquisition BTQ Technologies Corp. has made headlines with its recent acquisition of advanced computing-in-memory (CIM) intellectual property from Cimtech Technology Co. This strategic move is intended to bolster BTQ's endeavors in post-quantum cryptography and quantum-secure communication technologies,...

Continue Reading
onsemi Expands Capabilities with Vcore Power Acquisition

Updated Category News Views 197

onsemi Completes Strategic Acquisition of Vcore Power Technology onsemi, a leading company in semiconductor technology, recently completed the acquisition of Vcore power technologies along with its associated intellectual property licenses from Aura Semiconductor. This acquisition marks a significant milestone in enhancing onsemi’s power management portfolio, which aims...

Continue Reading
BTQ Technologies Leverages Mitacs Grant for Quantum Research

Updated Category News Views 110

BTQ Technologies Partners with Mitacs BTQ Technologies has recently been awarded a Mitacs Elevate Postdoctoral Fellowship Grant worth $158,000. This grant is aimed at advancing research on quantum simulations, specifically focusing on methods to reduce the resource needs of such simulations, thereby accelerating progress in quantum computing. Innovative Research in...

Continue Reading
Zealand Pharma's H1 2025 Results Showcase Promising Growth

Updated Category News Views 367

Zealand Pharma's Promising Financial Position in H1 2025 In a significant update, Zealand Pharma A/S (NASDAQ: ZEAL), a biotechnology company dedicated to peptide-based medicines, has released its financial results for the first half of 2025. This report highlights the tremendous progress the company has made, including a fruitful collaboration with Roche and a robust...

Continue Reading